Hvivo will enrol healthy volunteers to test the efficacy of a biotech company’s oral vaccine candidate for Covid-19.
A subsidiary of Dublin-based pharma services company Open Orphan said it is developing the world’s first human challenge model involving the Omicron variant of Covid-19.
Open Orphan’s Hvivo subsidiary plans to manufacture a new challenge agent based on the Omicron strain of SARS-CoV-2. This will be used to test the efficacy of an oral vaccine candidate from biotech company Vaxart.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).